Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Attard, GerhardtBrown, LC
Clarke, N
Murphy, L
Cross, W
Jones, R
Gillessen, S
Russell, JM
Cook, A
Bowen, J
Lydon, A
Pedley, ID
Parikh, O
Chowdhury, S
Malik, Z
Matheson, D
Parker, C
Sydes, MR
Parmar, MK
James, ND
Issue Date
2021-09-01
Metadata
Show full item recordCitation
Attard, G., Brown, L.C., Clarke, N. et al. (2021) Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology, 32, S5, S1298.Publisher
ElsevierJournal
Annals of OncologyAdditional Links
https://www.annalsofoncology.org/article/S0923-7534(21)04402-1/fulltext#relatedArticlesType
OtherLanguage
enDescription
This is an accepted manuscript of an abstract published by Elsevier in Annals of Oncology on 01/09/2021, available online: https://doi.org/10.1016/j.annonc.2021.08.2098 The accepted version of the publication may differ from the final published version.ISSN
0923-7534EISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2021.08.2098
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/